These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 22413824)
21. Genetic vaccination for the active immunotherapy of cancer. Bronte V Curr Gene Ther; 2001 May; 1(1):53-100. PubMed ID: 12109138 [TBL] [Abstract][Full Text] [Related]
22. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Gulley JL; Arlen PM; Madan RA; Tsang KY; Pazdur MP; Skarupa L; Jones JL; Poole DJ; Higgins JP; Hodge JW; Cereda V; Vergati M; Steinberg SM; Halabi S; Jones E; Chen C; Parnes H; Wright JJ; Dahut WL; Schlom J Cancer Immunol Immunother; 2010 May; 59(5):663-74. PubMed ID: 19890632 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic vaccines for prostate cancer. Cha E; Fong L Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819 [TBL] [Abstract][Full Text] [Related]
25. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434 [TBL] [Abstract][Full Text] [Related]
26. The role of poxviruses in tumor immunotherapy. Kaufman HL Surgery; 2003 Nov; 134(5):731-7. PubMed ID: 14639347 [No Abstract] [Full Text] [Related]
27. Methods for improving the immunogenicity and efficacy of cancer vaccines. Pilla L; Ferrone S; Maccalli C Expert Opin Biol Ther; 2018 Jul; 18(7):765-784. PubMed ID: 29874943 [TBL] [Abstract][Full Text] [Related]
28. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). McNeel DG; Chen YH; Gulley JL; Dwyer AJ; Madan RA; Carducci MA; DiPaola RS Hum Vaccin Immunother; 2015; 11(10):2469-74. PubMed ID: 26111351 [TBL] [Abstract][Full Text] [Related]
29. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. Parsons JK; Pinto PA; Pavlovich CP; Uchio E; Kim HL; Nguyen MN; Gulley JL; Jamieson C; Hsu P; Wojtowicz M; Parnes H; Schlom J; Dahut WL; Madan RA; Donahue RN; Chow HS Eur Urol Focus; 2018 Sep; 4(5):636-638. PubMed ID: 30197041 [TBL] [Abstract][Full Text] [Related]
30. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235 [TBL] [Abstract][Full Text] [Related]